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University of Leicester, Leicester, UKBackground. An imbalance in matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are implicated in AAA
formation. 3-Hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are known to reduce MMP levels. The
aim of this study was to investigate the in vivo effect of statins on MMP levels in AAA.
Methods. Infra-renal aortic biopsies were obtained from the anterior sac of 63 patients undergoing asymptomatic repair.
Seventeen patients were taking a statin pre-operatively, while 46 were not. The concentrations of MMP-1, -2, -3, -8, -9, -13,
TIMP-1 and TIMP-2 were quantified using ELISA.
Results. There was no difference in the concentration of MMP-1, -2, -8, -13, TIMP-1 or -2 in patients taking versus not
taking a statin pre-operatively. In contrast levels of MMP-9 and MMP-3 were significantly lower in patients taking a statin.
Conclusions. These data demonstrate that statins decrease MMP-9 and MMP-3 levels and represent a potential
pharmacotherapy in established AAA.Keywords: Abdominal aortic aneurysm; Matrix metalloproteinase; MMP-9; 3-Hydroxy-3-methylglutaryl coenzyme-A
reductase inhibitors.Introduction
Abdominal aortic aneurysm (AAA) formation is
associated with transmural aortic wall changes includ-
ing loss of extracellular matrix proteins (ECM), loss of
smooth muscle cells (SMC), and inflammatory cell
infiltration.1–3 In contrast, atherosclerosis is an intimal
and subintimal disease associated with endothelial cell
injury, monocyte migration with insudation of lipo-
proteins, and ECM accumulation.4–6 An imbalance in
matrix metalloproteinases (MMPs), and their inhibi-
tors (TIMPs), are implicated in both aneurysmal and
atherosclerotic disease.7,8
The beneficial role of 3-hydroxy-3-methylglutaryl
coenzyme-A reductase inhibitors (statins) in patients
with coronary and cerebrovascular atherosclerosis has
been conclusively established by large clinical trials.9,
10 The primary role of a statin is lipid lowering,
however, secondary actions, mediated through
mesenchymal cell inhibition11,12 are also described
and include the in vitro and in vivo suppression of
MMP production in atherosclerotic lesions13,14 and theng author. Prof. M.M. Thompson, Dept of Vascular
loor, St. James Wing, St. George’s Hospital NHS Trust,
oad, London, SW17 0QT, UK.
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aim of this study was to observe in vivo MMP
expression in the AAA wall of patients taking versus
not taking a statin pre-operatively.MethodsStudy design
Sixty-three patients with asymptomatic AAA, under-
going elective open repair, were studied. Ethical
approval for the study was obtained from the local
research ethics committee and consent was obtained in
accordance with guidelines. Seventeen patients were
taking a statin pre-operatively and 46 were not. Patient
demographic information including age, gender,
smoking history (current or ex-smoker of less than 10
years versus non-smoker or ex-smoker of greater than
10 years), presence of a cardiovascular event (docu-
mented myocardial infarction, cerebrovascular or
peripheral vascular disease, angina requiring medi-
cation), hypertension (requiring medication), or dia-
betes (requiring medication or dietary modification)
was recorded. Pharmacotherapy with cardiovascularEur J Vasc Endovasc Surg 30, 259–262 (2005)
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(beta-blocker, calcium channel blocker, acetylcholine-
esterase inhibitor and non-steroidal anti-
inflammatory).Protein extraction and quantification
Full-thickness biopsies of each patients AAA were
obtained intra-operatively from the anterior aneurysm
wall, 5 cm distal to the left renal vein. Samples were
meticulously washed in saline, dissected of luminal
thrombus and adipose tissue, and frozen in liquid
nitrogen prior to further processing. MMPs and TIMPs
were extracted from the biopsies by the method of
Vine and Powell.16 In brief, the samples were weighed,
homogenized in buffer, centrifuged and the super-
natant dialyzed overnight at 4 8C. A protein assay was
used to standardise the concentration of each protein
extract to 1 mg of protein per millilitre of extract.
Enzyme-linked immunosorbent assay kits (Amersham
Pharmacia Biotech, Buckinghamshire, UK) were used
to quantify the following MMPs from each AAA
protein extract; MMP-1, MMP-2, MMP-3, MMP-8,
MMP-13, TIMP-1 and TIMP-2 (total levels); MMP-9
(total and active fraction). The final concentration of
each MMP and TIMP was expressed as ng of target
protein per mg protein extract.Statistical methods
In all analyses, patients taking a statin were compared
to patients not taking a statin pre-operatively. Discrete
variables (gender, history of cardiovascular event,
hypertension, smoking, diabetes and medications)
were presented as actual numbers and compared
using Fischer’s exact test. The continuous variables ofTable 1. Characteristics of patients taking a statin and not taking a s
Characteristics Non-statin cohort (nZ
Mean age (range) 73 (G7)
Median AAA size 6 (4–10)
Gender distribution 41 males
Cardiovascular event 15
Hypertension 25
Smoking history 38
Diabetes 2
Beta-blocker 10
Calcium channel blocker 11
ACE inhibitor 11
Non-steroidal anti-inflammatory 20
Smoking history, current or ex-smoker of less than 10 years versus non
cardiovascular event, documented myocardial infarction, angina requi
hypertension, requiring medication; diabetes, requiring long term inte
beta-blocker, calcium channel blocker, acetylcholine-esterase (ACE) inh
* Comparison used independent t-test with group mean and range i
† Mann–Whitney U-test with median and range in cm, and Fisher’s
Eur J Vasc Endovasc Surg Vol 30, September 2005age and AAA diameter were compared using the
independent t-test andMann–Whitney U-test, respect-
ively. ELISA data were non-parametrically distribu-
ted, presented as median and interquartile ranges, and
compared using the Mann–Whitney U-test. Statistical
significance was set at p!0.01. The statistical package
of the social sciences (SPSS forWindows 11.1) was used.ResultsPatient characteristics
Patient demographics and therapeutic parameters
were comparable between the two patient cohorts
(Table 1). In particular the median AAA size and
pharmacotherapy were similar between the study
groups. The range of statin therapies used in the
statin-treated cohort included; six patients on simvas-
tatin (20 mg nZ2, 40 mg nZ4); five patients on
atorvastastin (10 mg nZ1, 20 mg nZ3, 40 mg nZ1);
three patients on pravastatin (20 mg nZ2, 30 mg
nZ1).Concentration of MMPs and TIMPs within AAA biopsies
The levels of MMPs within the AAA wall of statin-
treated and non-treated patient cohorts are described
in Table 2. There was no difference in the concentration
of MMP-1, -2, -8 or-13, between patients on versus not
on a statin pre-operatively. In contrast the median
levels of total MMP-9 and MMP-3 were significantly
decreased in the statin-treated group (MMP-9, 8.65
versus 50.7 ng/mg, p!0.001:MMP-3, 1.42 versus
2.19 ng/mg, pZ0.009). The active fraction of MMP-9
was also lower in patients taking a statin pre-tatin prior to open abdominal aorta aneurysm repair
46) Statin cohort (nZ17) p-value
70 (G7.2) 0.151*
7 (5–10) 0.201†
17 males 0.312
6 1
14 0.078
13 0.719
4 0.041
7 0.199
6 0.523
8 0.120
6 0.774
-smoker or ex-smoker of greater than 10 years; presence of a
ring medication, cerebrovascular or peripheral vascular disease;
rvention including dietary modification. Pharmacotherapy included
ibitor and non-steroidal anti-inflammatory.
n years.
exact test, p!0.01.
Table 2. Concentration of MMP’s and TIMPs in the anterior aneurysm wall of patients taking a statin versus not taking a statin prior to
open abdominal aorta aneurysm repair
Enzyme group Non-statin cohort (nZ46) Statin cohort (nZ17) p-value
Collagenases
MMP-1 1.78 (1.24–3.47) 1.15 (0.55–3.95) 0.196
MMP-8 17.6 (8.45–34.5) 14.7 (5.49–18.5) 0.102
MMP-13 0.07 (0.05–0.11) 0.07 (0.04–0.11) 0.701
Elastases
MMP-2 45.5 (33.8–94.2) 62.0 (34.2–87.8) 0.775
MMP-9 (total) 50.7 (14.4–103) 8.65 (2.71–29.3) !0.001*
MMP-9 (active fraction) 3.36 (1.97–5.65) 1.87 (1.01–3.83) 0.012
Stromelysin
MMP-3 2.19 (1.41–3.88) 1.42 (1.12–1.88) 0.009*
Tissue Inhibitors
TIMP-1 141 (53.5–234) 226 (130–269) 0.033
TIMP-2 7.61 (4.13–15.3) 11.8 (4.46–25.0) 0.200
MMP and TIMP concentrations shown as median and interquartile range, units ng of target protein per mg of protein extract, compared with
Mann–Whitney U-test, p!0.01. *, significant.
Statins Decrease MMPs in AAA 261operatively, however, after consideration of multiple
hypotheses testing this difference was of borderline
significance (1.87 versus 3.36 ng/mg, pZ 0.012). The
median level of TIMP-1, MMP-9’s endogenous inhibi-
tor, was raised in patients taking a statin, however, this
increase did not reach significance (226 versus 141 ng/
mg, pZ0.033). The median level of TIMP-2 was not
significantly different between the patient cohorts.Discussion
Statins decrease LDL cholesterol by competitive
inhibition of the enzyme, 3-hydroxy-3-methylglutaryl
coenzyme-A reductase.17 Interestingly the coronary
and cerebrovascular effects of statins extend to
patients with normal LDL cholesterol and it is now
recognized that statins offer benefits far beyond that of
simple LDL lowering.9,10,18 The unanticipated effects
of statins may result from a build up of the
intermediates of cholesterol metabolism19 which
have an inhibitory effect on cellular function, reducing
endothelial cell adhesion,20 increasing apoptosis in
smooth muscle cells,12 and reducing inflammatory cell
activation.11,21
The process of aneurysm formation may be nega-
tively influenced by statins, however, there is little
evidence to support this hypothesis with only tissue-
explant models suggesting a decrease in MMP-9 levels
by immunohistochemistry.15 The findings from our in
vivo study suggest that statins are associated with a
generalised lowering of protease levels in established
AAA. Though this effect was non-significant for most
MMPs, a significant lowering of the elastase MMP-9 at
both total and active levels, and a decrease in total
MMP-3 was observed. A reduction in MMP-9
expression is important since, it is strongly implicatedin all stages of AAA pathogenesis from inception to
rupture.22,23 The site of AAAwall biopsy, 5 cm distal to
the left renal vein rather than at the point of maximal
AAA dilatation was considered since this represents a
zone of proximal transition where the process of
aneurysmal degeneration is likely to be most aggres-
sive.24 The shift in MMP-9/TIMP-1 enzyme dynamics
may cause a four-fold drop in elastase activity at the
transition zone.
This study was not without its limitations. The
study was based on a single time-point observation
and lacked any power to predict the effects of statins
on AAA expansion. However, single point observa-
tional studies probably reflect community-based com-
pliance to medications more accurately than
longitudinal clinical trials, which may have greater
compliance. Secondly the overall benefit attributed to
statins in an atherosclerotic population, may not be
transferable to an AAA population. For example
smooth muscle cell apoptosis is a recognised feature
of AAA formation2 but is also associated with statin
use.12 While this effect may be of benefit in athero-
sclerosis,25 it may potentially hasten AAA growth.
Thus, the commitment to a randomised, intension-to-
treat study is necessary prior to the generalised
acceptance of statins in the treatment AAA patients.
In conclusion the association of statins with a
lowering of MMP-3 and-9 in established AAA may
slow further progression, but is only a small part if a
complex biological interaction.References
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